Invention Accelerator Program

Stronger Together

A long-time partner of Stanford Biodesign, Fogarty Innovation is an educational incubator that provides hands-on training and mentoring to help innovators transform promising product or service ideas into successful, sustainable businesses. Their team of seasoned executives and innovators have created and/or brought to market a wide range of health technology innovations that provide significant benefits to patients.

Working together, we have developed an invention accelerator program (IAP) to address the gap between promising translational projects and their ability to launch as viable businesses that can deliver innovative new technologies to patients.

Invention Accelerator Program

Invention Accelerator Program

The IAP is a competitive program that helps entrepreneurs early in the innovation process to accelerate the time from discovery to actual deployment of their inventions into patient care.

“Patients, providers, and our society at large all benefit when academic research translates into meaningful, accessible medical technologies.”

– Andrew Cleeland, CEO, Fogarty Innovation

The IAP identifies promising ideas sourced from hospitals, universities, and individual inventors, and then collaborates with the entrepreneurs to validate their needs and advance their concepts. Specific goals include maturation of the technology, an assessment of the drivers and obstacles to commercialization, and exposure to a broad network of partners and other resources to fuel swift progress.

 

Over the course of four to six months, project teams participate in high-touch mentoring from seasoned industry veterans to address:

  • Needs validation
  • Product design
  • Prototype refinement
  • Early preclinical/clinical testing
  • IP assessment and strategy
  • Market size and segmentation
  • Regulatory pathway
  • Payment/reimbursement
  • Business model development
  • Fundraising
  • Team development

Admission Guidelines

To learn more about the IAP or apply, contact Brandon Felkins or John Morriss.